The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report
Cureus · 05.08.2024
DOI: 10.7759/cureus.66240 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 05.08.2024. Verfasst von Caitlyn H Livingston und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscinces, Texas A&M University, College Station, USA. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuroscinces, Texas A&M University, College Station, USA.
- Medical Oncology, Calvary Mater, Newcastle, AUS.
Zitieren
APA
Livingston, C. H., & Harper, B. (2024). The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report. Cureus. https://doi.org/10.7759/cureus.66240
Vancouver
Livingston CH, Harper B. The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report. Cureus. 2024. doi:10.7759/cureus.66240
BibTeX
@article{Livingston2024,
author = {Livingston, Caitlyn H and Harper, Benjamin},
title = {The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report},
journal = {Cureus},
year = {2024},
doi = {10.7759/cureus.66240}
}
EUVIMED